Abstract | PURPOSE: METHODS: Selective literature search was used for this study. RESULTS: In healthy women, HRT increases risks for venous thromboembolism and ischemic stroke, but for cardiovascular disease apparently only beyond 10 years after menopause or 60 years of age. Limited data in women with cardio or cerebrovascular disease have not demonstrated an increased risk for a vascular recurrent event, but for the first year after initiation. In HRT users affected by a cardiovascular event continuation of HRT has not been found to be associated with adverse outcome. Low dose estradiol--preferentially as transdermal patches, if necessary combined with metabolically neutral progestins--appears to convey lower risk. CONCLUSIONS: Safety data on HRT in survivors of cardiovascular events or ischemic stroke are limited, but exceptionally increased risk appears to be excluded. If off-label use of HRT is considered to be initiated or continued in women with cardio- or cerebrovascular disease, extensive counseling on the pros and cons of HRT is mandatory.
|
Authors | Eberhard Windler, Petra Stute, Olaf Ortmann, Alfred O Mueck |
Journal | Archives of gynecology and obstetrics
(Arch Gynecol Obstet)
Vol. 291
Issue 1
Pg. 213-7
(Jan 2015)
ISSN: 1432-0711 [Electronic] Germany |
PMID | 25322975
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Cardiovascular Diseases
(epidemiology)
- Estradiol
(administration & dosage)
- Estrogen Replacement Therapy
(adverse effects, methods)
- Female
- Humans
- Middle Aged
- Postmenopause
- Progestins
(administration & dosage)
- Risk
- Stroke
(epidemiology)
- Venous Thromboembolism
(epidemiology)
|